glucagon-like peptide-1 receptor agonist + insulin

**Glucagon-like peptide-1 receptor agonist + insulin** is a combination therapy strategy used primarily for type 2 diabetes, pairing a **GLP-1 receptor agonist (GLP-1RA)**—which mimics the incretin hormone GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety—with **basal insulin** to provide steady-state blood glucose control. This approach offers complementary mechanisms that improve glycemic control (e.g., HbA1c reductions of 0.5-1.4%), often with benefits like weight loss (typically 2-10 kg) and reduced hypoglycemia risk compared to insulin intensification alone. Fixed-ratio formulations (e.g., insulin degludec/liraglutide or insulin glargine/lixisenatide) simplify dosing; the strategy is supported by meta-analyses of RCTs showing noninferiority to basal-bolus regimens with better tolerability, positioning it as an advancement for patients inadequately controlled on oral agents or basal insulin.[1][2][3][5]

Brand names

Soliqua 100/33Xultophy

Other names

GLP-1RA + insulinGLP-1 receptor agonist + basal insulinGLP-1RA + basal insulin